| Year |
Citation |
Score |
| 2023 |
Chaudhary R, Slebos RJC, Noel LC, Song F, Poole MI, Hoening DS, Hernandez-Prera JC, Conejo-Garcia JR, Guevara-Patino JA, Wang X, Xie M, Tan AC, Chung CH. EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma. Cancer Research Communications. 3: 896-907. PMID 37377902 DOI: 10.1158/2767-9764.CRC-22-0443 |
0.349 |
|
| 2023 |
Alem D, Yang X, Beato F, Sarcar B, Tassielli AF, Dai R, Hogenson TL, Park MA, Jiang K, Cai J, Yuan Y, Fernandez-Zapico ME, Tan AC, Fleming JB, Xie H. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer. Molecular Carcinogenesis. PMID 37042566 DOI: 10.1002/mc.23543 |
0.314 |
|
| 2023 |
Rose MM, Espinoza VL, Hoff KJ, Pike LA, Sharma V, Hofmann MC, Tan AC, Pozdeyev N, Schweppe RE. BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer. Cancers. 15. PMID 36672327 DOI: 10.3390/cancers15020378 |
0.402 |
|
| 2022 |
Napoli M, Wu SJ, Gore BL, Abbas H, Lee K, Checker R, Dhar S, Rajapakshe K, Tan AC, Lee MG, Coarfa C, Flores ER. ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer. Nature Communications. 13: 614. PMID 35105868 DOI: 10.1038/s41467-022-28202-1 |
0.304 |
|
| 2021 |
Chai AWY, Tan AC, Cheong SC. Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis. Scientific Reports. 11: 23933. PMID 34907286 DOI: 10.1038/s41598-021-03418-1 |
0.312 |
|
| 2021 |
Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouët-Astrié C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 represents a therapeutic vulnerability in acquired BRAF/MEK inhibitor resistant melanoma. Molecular Cancer Therapeutics. PMID 34376578 DOI: 10.1158/1535-7163.MCT-20-1126 |
0.398 |
|
| 2021 |
Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. Npj Precision Oncology. 5: 41. PMID 34001994 DOI: 10.1038/s41698-021-00181-4 |
0.653 |
|
| 2021 |
Schubert L, Le AT, Estrada-Bernal A, Doak AE, Yoo M, Ferrara SE, Goodspeed A, Kinose F, Rix U, Tan AC, Doebele RC. . Molecular Pharmacology. PMID 33795352 DOI: 10.1124/molpharm.120.000207 |
0.435 |
|
| 2020 |
Chaudhary R, Slebos RJC, Song F, McCleary-Sharpe KP, Masannat J, Tan AC, Wang X, Amaladas N, Wu W, Hall GE, Conejo-Garcia JR, Hernanez-Prera JC, Chung CH. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Molecular Carcinogenesis. PMID 33378592 DOI: 10.1002/mc.23275 |
0.306 |
|
| 2020 |
He T, Wildey G, McColl K, Savadelis A, Spainhower K, McColl C, Kresak A, Tan AC, Yang M, Abbas A, Dowlati A. Identification of RUNX1T1 as a potential epigenetic modifier in small cell lung cancer. Molecular Oncology. PMID 33084222 DOI: 10.1002/1878-0261.12829 |
0.372 |
|
| 2020 |
Amato CM, Hintzsche JD, Wells K, Applegate A, Gorden NT, Vorwald VM, Tobin RP, Nassar K, Shellman YG, Kim J, Medina TM, Rioth M, Lewis KD, McCarter MD, Gonzalez R, ... Tan AC, et al. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers. 12. PMID 32708981 DOI: 10.3390/Cancers12071943 |
0.393 |
|
| 2020 |
Kern JA, Kim J, Foster DG, Mishra R, Gardner EE, Poirier JT, Rivard C, Yu H, Finigan JH, Dowlati A, Rudin CM, Tan AC. Role of mTOR as an essential kinase in SCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32599072 DOI: 10.1016/J.Jtho.2020.05.026 |
0.486 |
|
| 2020 |
Iwanaga R, Truong BT, Hsu JY, Lambert KA, Vyas R, Orlicky D, Shellman YG, Tan AC, Ceol C, Artinger KB. Loss of prdm1a accelerates melanoma onset and progression. Molecular Carcinogenesis. PMID 32562448 DOI: 10.1002/Mc.23236 |
0.37 |
|
| 2020 |
Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gullick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, et al. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death & Disease. 11: 443. PMID 32513939 DOI: 10.1038/S41419-020-2646-2 |
0.401 |
|
| 2020 |
Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L With Preclinical Activity Against Colorectal Cancer. Molecular Cancer Therapeutics. PMID 32499299 DOI: 10.1158/1535-7163.MCT-20-0106 |
0.36 |
|
| 2020 |
Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, et al. Preclinical and Dose-Finding Phase 1 Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32414750 DOI: 10.1158/1078-0432.Ccr-19-3498 |
0.418 |
|
| 2020 |
Schreiber AR, Kar A, Goodspeed AE, Pozdeyev N, Somerset H, Raeburn CD, Tan AC, Leong S, Wierman ME, Kiseljak-Vassiliades K. Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report. Journal of the Endocrine Society. 4: bvaa017. PMID 32154490 DOI: 10.1210/Jendso/Bvaa017 |
0.365 |
|
| 2020 |
Keysar SB, Gomes N, Miller B, Jackson BC, Le PN, Morton JJ, Reisinger J, Chimed TS, Gomez KE, Nieto C, Frederick B, Pronk GJ, Somerset HL, Tan AC, Wang XJ, et al. Inhibiting translation elongation with SVC112 suppresses cancer stem cells and inhibits growth in head and neck squamous carcinoma. Cancer Research. PMID 31911553 DOI: 10.1158/0008-5472.Can-19-3232 |
0.435 |
|
| 2020 |
Chaudhary R, Slebos R, Song F, McCleary-Sharpe K, Masannat J, Tan AC, Wang X, Amaladas N, Wu W, Hall G, Chung CH. Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 38: e18541-e18541. DOI: 10.1200/jco.2020.38.15_suppl.e18541 |
0.307 |
|
| 2020 |
Mukherjee N, Skees J, Todd K, West D, Lambert K, Robinson W, Amato C, Couts K, Gullick RV, MacBeth M, Nassar K, Tan A, Zhai Z, Fujita M, Bagby S, et al. 674 The effective killing of the difficult-to-treat melanomas with the combinations of MCL1 inhibitors S63845/MIK665 plus Navitoclax Journal of Investigative Dermatology. 140. DOI: 10.1016/J.Jid.2020.03.686 |
0.334 |
|
| 2019 |
Wilding CP, Elms ML, Judson I, Tan AC, Jones RL, Huang PH. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Review of Anticancer Therapy. PMID 31665941 DOI: 10.1080/14737140.2019.1686979 |
0.38 |
|
| 2019 |
Samson JM, Menon DR, Smith DE, Baird E, Kitano T, Gao D, Tan AC, Fujita M. Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. Chemico-Biological Interactions. 108822. PMID 31580832 DOI: 10.1016/J.Cbi.2019.108822 |
0.449 |
|
| 2019 |
Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE. Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Molecular Pharmacology. PMID 31554698 DOI: 10.1124/Mol.119.117804 |
0.664 |
|
| 2019 |
Capasso A, Bagby SM, Dailey KL, Currimjee N, Yacob BW, Ionkina A, Frank JG, Kim DJ, George C, Lee YB, Benaim E, Gittleman B, Hartman SJ, Tan AC, Kim J, et al. First-in-class phosphorylated-p68 inhibitor RX-5902 inhibits β-catenin signaling and demonstrates anti-tumor activity in triple-negative breast cancer. Molecular Cancer Therapeutics. PMID 31488700 DOI: 10.1158/1535-7163.MCT-18-1334 |
0.312 |
|
| 2019 |
He T, Wildey G, McColl K, Kresak A, Tan A, Dowlati A. Defining the role of RUNX1T1 in "combined" small cell lung cancer. Journal of Clinical Oncology. 37: e20101-e20101. DOI: 10.1200/Jco.2019.37.15_Suppl.E20101 |
0.481 |
|
| 2019 |
Yu H, Merrick DT, Tsao M, Richards WG, Chirieac LR, Watson MA, Rivard CJ, Harpole DH, Bueno R, Bokhoven Av, Tan A, Hirsch FR, Franklin WA. Abstract 4550: Correlations between tumor mutation burden, inflammatory profile and histological characteristics of tumor microenvironment in early-stage squamous cell lung carcinoma Cancer Research. 79: 4550-4550. DOI: 10.1158/1538-7445.Sabcs18-4550 |
0.385 |
|
| 2019 |
Nassar KW, Hintzsche J, Bagby S, Langouet-Astrie C, Samson J, Amato C, Gordon N, Fujita M, Schweppe R, Robinson W, Tan A. Abstract B076: Uncoupling of the cell cycle pathway from the MAPK pathway in BRAF/MEK inhibitor resistant melanoma Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B076 |
0.471 |
|
| 2018 |
Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. PMID 30531837 DOI: 10.1038/S41388-018-0617-1 |
0.342 |
|
| 2018 |
Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, Li Y, Samson JM, Bagby S, Tan AC, Robinson WA, Messersmith WA, Fujita M. CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma. Cancer Research. PMID 30297536 DOI: 10.1158/0008-5472.Can-18-0330 |
0.44 |
|
| 2018 |
Parrish JK, McCann TS, Sechler M, Sobral LM, Ren W, Jones KL, Tan AC, Jedlicka P. The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. Oncotarget. 9: 33110-33123. PMID 30237855 DOI: 10.18632/Oncotarget.26011 |
0.324 |
|
| 2018 |
Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, DeGala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK. Reversal of Triple-negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immune-Suppression. Molecular Cancer Research : McR. PMID 30213797 DOI: 10.1158/1541-7786.Mcr-18-0246 |
0.32 |
|
| 2018 |
Suda K, Murakami I, Yu H, Kim J, Tan AC, Mizuuchi H, Rozeboom LM, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR. CD44 facilitates epithelial to mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer. Molecular Cancer Therapeutics. PMID 30049789 DOI: 10.1158/1535-7163.Mct-17-1279 |
0.464 |
|
| 2018 |
Oweida A, Hararah M, Phan AV, Binder DC, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey ET, et al. Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30042205 DOI: 10.1158/1078-0432.Ccr-18-1038 |
0.551 |
|
| 2018 |
Suda K, Kim J, Murakami I, Rozeboom L, Shimoji M, Shimizu S, Rivard CJ, Mitsudomi T, Tan AC, Hirsch FR. Innate genetic evolution of lung cancers and spatial heterogeneity: analysis of treatment naïve lesions. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29933065 DOI: 10.1016/J.Jtho.2018.05.039 |
0.347 |
|
| 2018 |
Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, et al. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell. PMID 29910151 DOI: 10.1016/J.Stem.2018.05.021 |
0.308 |
|
| 2018 |
Pozdeyev N, Gay L, Sokol ES, Hartmaier RJ, Deaver KE, Davis SN, French JD, Vanden Borre P, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29615459 DOI: 10.1158/1078-0432.Ccr-18-0373 |
0.302 |
|
| 2018 |
Keysar S, Eagles J, Miller B, Jackson BC, Chowdhury FN, Reisinger J, Chimed TS, Le PN, Morton JJ, Somerset H, Varella-Garcia M, Tan AC, Song JI, Bowles DW, Reyland ME, et al. Salivary gland cancer patient-derived xenografts enable characterization of cancer stem cells and new gene fusions associated with tumor progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29555661 DOI: 10.1158/1078-0432.Ccr-17-3871 |
0.405 |
|
| 2018 |
Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 9: 8823-8835. PMID 29507657 DOI: 10.18632/Oncotarget.24260 |
0.649 |
|
| 2018 |
Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Gail Eckhardt S, Pitts TM. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. Bmc Cancer. 18: 136. PMID 29402316 DOI: 10.1186/s12885-018-4036-z |
0.383 |
|
| 2018 |
Tentler J, Frank J, Kim D, George C, Lee Y, Ely B, Tan A, Kim J, Pitts T, Capasso A, Dailey K, Eckhardt G, Diamond J. Abstract P5-21-16: Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-21-16 |
0.439 |
|
| 2018 |
Diamond JR, Orth JD, Ionkina A, Dailey K, Pitts TM, Capasso A, Marcus JM, Burke RT, Davis SL, Kim J, Tan A, Eckhardt SG, Tentler JJ. Abstract B175: Rational combination of mTOR and Aurora kinase A inhibition in preclinical models of triple-negative breast cancer Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B175 |
0.476 |
|
| 2018 |
Suda K, Kim J, Murakami I, Rozeboom L, Rivard C, Mitsudomi T, Tan A, Hirsch F. P2.04-15 Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions Journal of Thoracic Oncology. 13: S736. DOI: 10.1016/J.Jtho.2018.08.1239 |
0.325 |
|
| 2017 |
Scott AJ, Song EK, Bagby S, Purkey A, McCarter M, Gajdos C, Quackenbush KS, Cross B, Pitts TM, Tan AC, Eckhardt SG, Fenton H, Arcaroli J, Messersmith WA. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. Plos One. 12: e0187173. PMID 29091939 DOI: 10.1371/journal.pone.0187173 |
0.323 |
|
| 2017 |
Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, ... ... Tan AC, et al. ALK inhibitor response in melanomas expressing EML4-ALK fusions and alternate ALK isoforms. Molecular Cancer Therapeutics. PMID 29054983 DOI: 10.1158/1535-7163.Mct-17-0472 |
0.42 |
|
| 2017 |
Zhang C, Liu Z, Bunker E, Ramirez A, Lee S, Peng Y, Tan AC, Eckhardt SG, Chapnick DA, Liu X. Sorafenib Targets the Mitochondrial Electron Transport Chain Complexes and ATP Synthase to Activate the PINK1-Parkin Pathway and Modulate Cellular Drug Response. The Journal of Biological Chemistry. PMID 28673964 DOI: 10.1074/Jbc.M117.783175 |
0.31 |
|
| 2017 |
Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Frontiers in Oncology. 7: 94. PMID 28555173 DOI: 10.3389/fonc.2017.00094 |
0.315 |
|
| 2017 |
Nelson-Taylor SK, Le AT, Yoo M, Schubert L, Mishall KM, Doak A, Varella-Garcia M, Tan AC, Doebele RC. Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling. Molecular Cancer Therapeutics. PMID 28500237 DOI: 10.1158/1535-7163.Mct-17-0008 |
0.479 |
|
| 2017 |
Ohm AM, Tan AC, Heasley LE, Reyland ME. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. Oncogene. PMID 28368426 DOI: 10.1038/Onc.2017.27 |
0.613 |
|
| 2017 |
Dimberg L, Towers CG, Behbakht K, Hotz T, Kim J, Fosmire SP, Porter CC, Tan AC, Thorburn A, Ford HL. A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Molecular Cancer Research : McR. PMID 28108622 DOI: 10.1158/1541-7786.Mcr-16-0234 |
0.406 |
|
| 2017 |
Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, ... ... Tan AC, et al. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. Journal of the National Cancer Institute. 109. PMID 27634934 DOI: 10.1093/Jnci/Djw189 |
0.322 |
|
| 2017 |
Suda K, Murakami I, Yu H, Kim J, Mizuuchi H, Ellison K, Rivard C, Tan A, Mitsudomi T, Hirsch F. PS06.01 CD44 Confers EMT Phenotypic Change Following Resistance to EGFR-TKIs in Lung Cancer Journal of Thoracic Oncology. 12: S1581-S1582. DOI: 10.1016/J.Jtho.2017.09.082 |
0.398 |
|
| 2017 |
Helfrich B, Scarborough H, Heasley L, Ryall K, Tan A, Degregori J, Bunn P. P3.02b-084 Rational Combinations to Improve Outcome for EGFR-TKIs in NSCLCs with EGFR Mutations Journal of Thoracic Oncology. 12: S1242. DOI: 10.1016/J.Jtho.2016.11.1751 |
0.592 |
|
| 2016 |
Harder B, Tian W, La Clair JJ, Tan AC, Ooi A, Chapman E, Zhang DD. Brusatol overcomes chemoresistance through inhibition of protein translation. Molecular Carcinogenesis. PMID 28019675 DOI: 10.1002/Mc.22609 |
0.325 |
|
| 2016 |
Turner J, Couts K, Sheren J, Saichaemchan S, Ariyawutyakorn W, Avolio I, Cabral E, Glogowska M, Amato C, Robinson S, Hintzsche J, Applegate A, Seelenfreund E, Gonzalez R, Wells K, ... ... Tan AC, et al. Kinase Gene Fusions in Defined Subsets of Melanoma. Pigment Cell & Melanoma Research. PMID 27864876 DOI: 10.1111/Pcmr.12560 |
0.389 |
|
| 2016 |
Zhang G, Scarborough H, Kim J, Rozhok AI, Chen YA, Zhang X, Song L, Bai Y, Fang B, Liu RZ, Koomen J, Tan AC, Degregori J, Haura EB. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. Science Signaling. 9: rs12. PMID 27811184 DOI: 10.1126/Scisignal.Aaf5011 |
0.366 |
|
| 2016 |
Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, et al. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 113: E6669-E6678. PMID 27791036 DOI: 10.1073/Pnas.1603876113 |
0.313 |
|
| 2016 |
Wong JP, Todd JR, Finetti MA, McCarthy F, Broncel M, Vyse S, Luczynski MT, Crosier S, Ryall KA, Holmes K, Payne LS, Daley F, Wai P, Jenks A, Tanos B, ... Tan AC, et al. Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. Cell Reports. 17: 1265-1275. PMID 27783942 DOI: 10.1016/J.Celrep.2016.10.005 |
0.511 |
|
| 2016 |
Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). Investigational New Drugs. PMID 27783255 DOI: 10.1007/s10637-016-0398-8 |
0.358 |
|
| 2016 |
Bagby S, Messersmith WA, Pitts TM, Capasso A, Varella-Garcia M, Klauck PJ, Kim J, Tan AC, Eckhardt SG, Tentler JJ, Arcaroli J. Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. Journal of Visualized Experiments : Jove. PMID 27768028 DOI: 10.3791/54393 |
0.374 |
|
| 2016 |
Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27702820 DOI: 10.1158/1078-0432.Ccr-15-2851 |
0.355 |
|
| 2016 |
Scarborough HA, Helfrich BA, Casas-Selves M, Schuller A, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663586 DOI: 10.1158/1078-0432.Ccr-16-1179 |
0.513 |
|
| 2016 |
Todd JR, Ryall KA, Vyse S, Wong JP, Natrajan RC, Yuan Y, Tan AC, Huang PH. Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. Oncotarget. PMID 27556857 DOI: 10.18632/Oncotarget.11307 |
0.393 |
|
| 2016 |
Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA. Barasertib,(AZD1152)a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Molecular Cancer Therapeutics. PMID 27496133 DOI: 10.1158/1535-7163.Mct-16-0298 |
0.459 |
|
| 2016 |
Tan AC, Vyse S, Huang PH. Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discovery Today. PMID 27452454 DOI: 10.1016/J.Drudis.2016.07.010 |
0.435 |
|
| 2016 |
Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, et al. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget. PMID 27385211 DOI: 10.18632/oncotarget.10366 |
0.318 |
|
| 2016 |
Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE. The Mitogen Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor, Dasatinib, in Thyroid Cancer. Molecular Cancer Therapeutics. PMID 27222538 DOI: 10.1158/1535-7163.Mct-15-0702 |
0.392 |
|
| 2016 |
Symonds JM, Ohm AM, Tan AC, Reyland ME. PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells. Oncotarget. PMID 26918447 DOI: 10.18632/Oncotarget.7560 |
0.422 |
|
| 2016 |
Lieu CH, Pitts TM, Kim J, Tan A, Messersmith WA, You YN, Eng C, Eckhardt SG. Emerging transcriptional landscape and putative therapeutic targets in young patients with metastatic colorectal cancer (CRC). Journal of Clinical Oncology. 34: 605-605. DOI: 10.1200/Jco.2016.34.4_Suppl.605 |
0.368 |
|
| 2016 |
Lieu CH, Golemis E, Kim J, Serebriiskii I, Bailey M, Tan A, Pitts TM, Eng C, Ennis R, Eckhardt SG, Frampton GM, Meyer JE. Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC). Journal of Clinical Oncology. 34: 3589-3589. DOI: 10.1200/Jco.2016.34.15_Suppl.3589 |
0.312 |
|
| 2016 |
Meyer JE, Serebriiskii I, Lieu CH, Frampton GM, Bailey M, Ennis R, Tan A, Kim J, Golemis E. Genomic distinctions between colon and rectal cancer in young patients. Journal of Clinical Oncology. 34: 3574-3574. DOI: 10.1200/Jco.2016.34.15_Suppl.3574 |
0.374 |
|
| 2015 |
Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt S, Heasley LE, Kang J, Tan AC. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. Bmc Genomics. 16: S2. PMID 26681397 DOI: 10.1186/1471-2164-16-S12-S2 |
0.607 |
|
| 2015 |
Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget. PMID 26439693 DOI: 10.18632/oncotarget.5949 |
0.336 |
|
| 2015 |
Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Research. 75: 4398-406. PMID 26359452 DOI: 10.1158/0008-5472.Can-15-0509 |
0.69 |
|
| 2015 |
Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC. Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. Bioinformatics (Oxford, England). PMID 26206305 DOI: 10.1093/Bioinformatics/Btv427 |
0.621 |
|
| 2015 |
Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG. Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Frontiers in Pharmacology. 6: 120. PMID 26136684 DOI: 10.3389/fphar.2015.00120 |
0.423 |
|
| 2015 |
Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Mässenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, ... ... Tan AC, et al. FGFR1 expression levels predict BGJ398-sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26015511 DOI: 10.1158/1078-0432.Ccr-14-3357 |
0.654 |
|
| 2015 |
Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE. An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. Plos One. 10: e0123600. PMID 25946135 DOI: 10.1371/Journal.Pone.0123600 |
0.663 |
|
| 2015 |
Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, Gan G, McGettigan B, Fernandez P, Padilla-Just N, Varella-Garcia M, ... ... Tan AC, et al. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene. PMID 25893296 DOI: 10.1038/Onc.2015.94 |
0.366 |
|
| 2015 |
Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14: 1117-29. PMID 25758253 DOI: 10.1158/1535-7163.Mct-14-0538-T |
0.306 |
|
| 2015 |
Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis SL, Klauck PJ, Pitts TM, Gangolli E, Fabrey R, O'Connell SM, Vincent PW, Eckhardt SG. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Molecular Cancer Therapeutics. 14: 317-25. PMID 25376610 DOI: 10.1158/1535-7163.MCT-13-1012 |
0.344 |
|
| 2015 |
Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, et al. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. International Journal of Cancer. Journal International Du Cancer. 136: 1967-75. PMID 25242168 DOI: 10.1002/Ijc.29225 |
0.354 |
|
| 2014 |
Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. Plos One. 9: e113037. PMID 25401499 DOI: 10.1371/journal.pone.0113037 |
0.368 |
|
| 2014 |
Wang CA, Drasin D, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello JC, Tan AC, Ford HL. Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. Cancer Research. 74: 7357-70. PMID 25348955 DOI: 10.1158/0008-5472.Can-14-0666 |
0.337 |
|
| 2014 |
Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics (Oxford, England). 30: 2393-8. PMID 24812339 DOI: 10.1093/Bioinformatics/Btu323 |
0.647 |
|
| 2014 |
Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, ... ... Tan AC, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3299-309. PMID 24771645 DOI: 10.1158/1078-0432.CCR-13-3060 |
0.624 |
|
| 2014 |
Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Molecular Cancer. 13: 62. PMID 24645981 DOI: 10.1186/1476-4598-13-62 |
0.388 |
|
| 2014 |
Golan T, Eckhardt SG, Stossel C, Atias D, Wang G, Pitts TM, Aisner D, Weekes CD, Berger R, Tan A. RNA-seq and KRAS mutational status in ascitic pancreatic cancer cells: Novel results and distinct subsets. Journal of Clinical Oncology. 32: e15214-e15214. DOI: 10.1200/Jco.2014.32.15_Suppl.E15214 |
0.381 |
|
| 2013 |
Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. Plos One. 8: e82236. PMID 24349229 DOI: 10.1371/Journal.Pone.0082236 |
0.685 |
|
| 2013 |
Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, Spreafico A, Kachaeva MI, Selby HM, Tentler JJ, Eckhardt SG, Leong S. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6219-29. PMID 24045180 DOI: 10.1158/1078-0432.CCR-13-0145 |
0.355 |
|
| 2013 |
Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, Aisner DL, Wilhelm F, ... ... Tan AC, et al. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Molecular Cancer Therapeutics. 12: 1994-2005. PMID 23873848 DOI: 10.1158/1535-7163.Mct-13-0206 |
0.436 |
|
| 2013 |
Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, Tai WM, Winn RA, Bikkavilli K, Vanscoyk M, Eckhardt SG, et al. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model. British Journal of Cancer. 109: 667-75. PMID 23868008 DOI: 10.1038/Bjc.2013.361 |
0.342 |
|
| 2013 |
Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, Brandão LN, Winges A, Sawczyn KK, Liang X, Keating AK, Tan AC, Earp HS, Graham DK. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood. 122: 1599-609. PMID 23861246 DOI: 10.1182/Blood-2013-01-478156 |
0.313 |
|
| 2013 |
Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4149-62. PMID 23757356 DOI: 10.1158/1078-0432.Ccr-12-3140 |
0.437 |
|
| 2013 |
Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, ... ... Tan AC, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Molecular Oncology. 7: 776-90. PMID 23607916 DOI: 10.1016/J.Molonc.2013.03.004 |
0.447 |
|
| 2013 |
Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of Clinical Investigation. 123: 2257-67. PMID 23585477 DOI: 10.1172/Jci67816 |
0.402 |
|
| 2013 |
Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in Pharmacology. 4: 35. PMID 23543898 DOI: 10.3389/Fphar.2013.00035 |
0.486 |
|
| 2013 |
Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Molecular Pharmacology. 83: 882-93. PMID 23371912 DOI: 10.1124/Mol.112.084111 |
0.625 |
|
| 2013 |
Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 291-303. PMID 23136197 DOI: 10.1158/1078-0432.CCR-12-1611 |
0.337 |
|
| 2013 |
Wang C, Jedlicka P, Tan A, Pham C, Zaberezhnvv V, Ford H. Abstract PR04: The Six2 homeoprotein mediates breast cancer metastasis via repressing E-cadherin Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-Pr04 |
0.406 |
|
| 2013 |
Schlegel J, Sambade M, Sather S, Moschos S, Tan A, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt G, Kuan P, Hamilton RL, Duncan LM, Miller CR, et al. Abstract 3037: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma. Cancer Research. 73: 3037-3037. DOI: 10.1158/1538-7445.Am2013-3037 |
0.482 |
|
| 2013 |
Wang C, Jedlicka P, Zaberezhnyy V, Tan A, Ford H. Abstract 2705: Novel functions of the homeoprotein SIX2 in mediating anchorage independence and metastasis in breast cancer. Cancer Research. 73: 2705-2705. DOI: 10.1158/1538-7445.Am2013-2705 |
0.432 |
|
| 2013 |
Dimberg LY, Cabrera J, Menke C, Kim J, Porter CC, Tan A, Behbakht K, Thorburn A, Ford HL. Abstract B115: Use of a genome-wide loss-of-function screen to identify novel mechanisms of resistance to TRAIL induced apoptosis. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B115 |
0.446 |
|
| 2013 |
Diamond J, Tan A, Ionkina A, Newton T, Pitts T, Eckhardt S, Tentler J. Abstract P2-09-06: The role of p53 family tumor suppressors in mediating response to aurora kinase inhibition in triple-negative breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P2-09-06 |
0.392 |
|
| 2012 |
Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Medicine. 1: 207-17. PMID 23342270 DOI: 10.1002/cam4.27 |
0.324 |
|
| 2012 |
Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Research. 72: 4154-64. PMID 22738915 DOI: 10.1158/0008-5472.Can-11-2848 |
0.429 |
|
| 2012 |
Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature Chemical Biology. 8: 646-54. PMID 22660439 DOI: 10.1038/Nchembio.965 |
0.301 |
|
| 2012 |
Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM, Spreafico A, Varella-Garcia M, Bemis L, Tan AC, Reinemann JM, Touban BM, Dasari A, Eckhardt SG, Messersmith WA. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2704-14. PMID 22553375 DOI: 10.1158/1078-0432.CCR-11-3167 |
0.317 |
|
| 2012 |
Pilling AB, Le AT, Tan A, Kim J, Singleton KR, Heasley LE, Helfrich B, DeGregori J, Doebele RC. Abstract 5594: ALK-driven lung cancer: Potential therapeutic strategies for treatment and prevention of drug resistance Cancer Research. 72: 5594-5594. DOI: 10.1158/1538-7445.Am2012-5594 |
0.688 |
|
| 2012 |
Singleton KR, Tan A, Kim J, Heasley L. Abstract B35: Alternate receptor tyrosine kinases provide protection from FGFR inhibition in HNSCC cells as identified by genome-wide shRNA screening Clinical Cancer Research. 18: B35-B35. DOI: 10.1158/1078-0432.Mechres-B35 |
0.686 |
|
| 2012 |
Bradshaw-Pierce EL, Pitts TM, McPhillips KL, Gustafson DL, Tan A, Nguyen L, West M, Fisher T, Murray BW, Eckhardt SG. Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer Clinical Cancer Research. 18: A46-A46. DOI: 10.1158/1078-0432.Mechres-A46 |
0.428 |
|
| 2012 |
Pitts T, McPhillips K, Selby H, Spreafico A, Bagby S, Britt B, Tentler J, Tan A, Kuida K, Eckhardt S. 562 Antitumor Activity of the Polo-like Kinase (PLK) Inhibitor, TAK-960, Alone and in Combination with Standard Agents Against KRAS WT and MT Colorectal Cancer (CRC) Models European Journal of Cancer. 48: 172-173. DOI: 10.1016/S0959-8049(12)72359-6 |
0.305 |
|
| 2012 |
Tan A, Britt B, Astling D, Leong S, Lieu C, Tentler J, Pitts T, Arcaroli J, Messersmith W, Eckhardt S. 263 Validation of Preclinical Colorectal Cancer Models Against TCGA Data for Pathway Analysis and Predictive Biomarker Discovery European Journal of Cancer. 48: 81. DOI: 10.1016/S0959-8049(12)72061-0 |
0.341 |
|
| 2011 |
Im E, Pitts TM, Kulikowski G, Tan A, Tentler JJ, Murray B, Carley W, Smeal T, Guo C, Eckhardt SG. Contribution of the epithelial-mesenchymal (EMT) phenotype to the sensitivity of colorectal cancer cell lines to the p21-activated kinase inhibitor, PF-3758309. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 438. PMID 27985853 DOI: 10.1200/Jco.2011.29.4_Suppl.438 |
0.462 |
|
| 2011 |
Spreafico A, Tentler JJ, Tan A, Pitts TM, Kachaeva MI, Selby HM, Eckhardt SG. Evaluation of antiproliferative and apoptotic effects of the rational combination of the MEK1/2 inhibitor selumetinib (AZD6244) and inhibitors of the hedgehog pathway in colorectal cancer (CRC) cell lines. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 422. PMID 27985816 DOI: 10.1200/Jco.2011.29.4_Suppl.422 |
0.496 |
|
| 2011 |
Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Zaberezhnyy V, Gao D, Tan AC, DeGregori J. Genome-Wide shRNA Screen Identifies WEE1 As a Critical Mediator of Cell Fate and Novel Therapeutic Target in AML, Blood. 118: 3503-3503. DOI: 10.1182/Blood.V118.21.3503.3503 |
0.331 |
|
| 2011 |
Diamond J, Eckhardt S, Tan A, Selby H, Newton T, Pitts T, Bray, Fletcher G, Tentler J. P3-01-08: In Vitro and In Vivo Antitumor Activity of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Triple-Negative Breast Cancer Models. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-01-08 |
0.436 |
|
| 2010 |
Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5581-90. PMID 21062932 DOI: 10.1158/1078-0432.CCR-10-0851 |
0.37 |
|
| 2010 |
Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5436-46. PMID 20943761 DOI: 10.1158/1078-0432.Ccr-10-2054 |
0.346 |
|
| 2010 |
Keysar S, Anderson R, Takimoto S, Tan A, Deyneko I, McGovern K, Ross RW, Song J, Jimeno A. Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC). Journal of Clinical Oncology. 28: 5558-5558. DOI: 10.1200/Jco.2010.28.15_Suppl.5558 |
0.456 |
|
| 2010 |
Varella-Garcia M, Flacco A, Cho YG, Tan A, Kono S, Franklin W, Cappuzzo F, Crino L, Doebele R, Camidge DR. Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events Cancer Research. 70: 812-812. DOI: 10.1158/1538-7445.Am10-812 |
0.469 |
|
| 2009 |
Garrido-Laguna I, Rudek M, Tan A, Uson M, Iacobuzio-Donahue C, Angenendt M, Jimeno A, Laheru D, Barret M, Hidalgo M. Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4612. PMID 27964189 DOI: 10.1200/Jco.2009.27.15_Suppl.4612 |
0.364 |
|
| 2009 |
Tan A, Jimeno A, Garrido-Laguna I, Uson M, De Oliveira E, Wilson A, Rubio-Viqueira B, Rajeshkumar NV, Hidalgo M. Use of amolecular mimicry approach to identify effective agents in pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4603. PMID 27964150 DOI: 10.1200/Jco.2009.27.15_Suppl.4603 |
0.343 |
|
| 2009 |
Messersmith WA, Rajeshkumar NV, Tan AC, Wang XF, Diesl V, Choe SE, Follettie M, Coughlin C, Boschelli F, Garcia-Garcia E, Lopez-Rios F, Jimeno A, Hidalgo M. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Molecular Cancer Therapeutics. 8: 1484-93. PMID 19509264 DOI: 10.1158/1535-7163.MCT-09-0075 |
0.362 |
|
| 2008 |
Song D, Chaerkady R, Tan AC, García-García E, Nalli A, Suárez-Gauthier A, López-Ríos F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, Jimeno A, Pandey A, Hidalgo M. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Molecular Cancer Therapeutics. 7: 3275-84. PMID 18852131 DOI: 10.1158/1535-7163.Mct-08-0508 |
0.33 |
|
| Show low-probability matches. |